623900-99-2Relevant articles and documents
Optimization of novel combi-molecules: Identification of balanced and mixed bcr-abl/DNA targeting properties
Rachid, Zakaria,Katsoulas, Athanasia,Williams, Christopher,Larroque, Anne-Laure,McNamee, James,Jean-Claude, Bertrand J.
, p. 4248 - 4253 (2007)
Steps toward the identification of combi-molecules with strong abl tyrosine kinase (TK) inhibitory property and significant DNA damaging potential are described. The optimized combi-molecule 13a was shown to induce approximately twofold stronger abl TK in
Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors
Lü, Shuang,Luo, Qun,Hao, Xiang,Li, Xianchan,Ji, Liyun,Zheng, Wei,Wang, Fuyi
experimental part, p. 6964 - 6968 (2012/01/05)
Six analogs of imatinib, an Abl kinase inhibitor clinically used as a first-line therapeutic agent for chronic myeloid leukaemia (CML), have been synthesized and characterized. And their potency as Abl kinase inhibitors have been screened by a robust virt
Synthesis of pyrimidinopyridine-triazene conjugates targeted to abl tyrosine kinase
Rachid, Zakaria,Katsoulas, Athanasia,Brahimi, Fouad,Jean-Claude, Bertrand Jacques
, p. 3297 - 3300 (2007/10/03)
The synthesis and abl tyrosine kinase inhibitory activities of alkyltriazenes conjugated to phenylaminopyrimidines are described. Significant abl inhibitory activities were observed only when a benzamido spacer was inserted between the 1,2,3-triazene chai
